Use of gabapentin in the treatment of childhood reflex sympathetic dystrophy.
Reflex sympathetic dystrophy, a painful syndrome involving an extremity after trauma or injury, is increasingly reported in the pediatric population. Although no clear pathophysiologic mechanism for this disorder has been identified, the role of central serotonin activity seems important. Gabapentin, a new antiepileptic medication, has been demonstrated to be effective in adults with reflex sympathetic dystrophy. The first reported case of a child with a diagnosis of reflex sympathetic dystrophy who was treated successfully with gabapentin is presented.
Wheeler
D S
DS
Department of Pediatrics and Clinical Investigations, Naval Medical Center, San Diego, California, USA.
Vaux
K K
KK
Tam
D A
DA
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000588:Amines; D002648:Child; D003509:Cyclohexanecarboxylic Acids; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D007866:Leg / Q000601:surgery*; D012008:Recurrence; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin